Search results
Why Is Novavax (NVAX) Stock Up 20% Today?
InvestorPlace· 4 hours agoNovavax (NASDAQ:NVAX) is on a recovery trek after collapsing in late 2021. Regarding timeline, the latter two firms said that they would be able to...
What's Going On With Novavax Stock? - Novavax (NASDAQ:NVAX)
Benzinga· 8 hours agoNovavax, Inc. NVAX shares are trading higher Wednesday, and the stock is up by more than 300% over...
FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall
CNN.com· 3 hours agoThe US Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday...
Novavax Says It Can Deliver Recommended Covid Vaccine in September
Market Watch· 4 hours agoNovavax said it expected it would be able to deliver a vaccine targeting the strain of Covid-19 recommended by a regulatory advisory group in the U.S. by September. The U.S ...
FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines
Scripps News via AOL· 44 minutes agoGovernment advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines...
New COVID-19 vaccine for fall should target JN.1 lineage, not variant, FDA panel
USA TODAY via Yahoo News· 6 hours agoOfficials noted that COVID-19 is rapidly evolving. The goal of the group was to capture the virus’...
COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say
Reuters via Yahoo News· 12 hours agoThe 16 advisors did not vote on whether to favor the original JN.1 variant or one of its successors...
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
Zacks via Yahoo Finance· 1 day agoAn FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to...
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say
Reuters· 12 hours agoCOVID-19 vaccine makers said data from animals studies showed their 2024-25 shots targeting the JN.1...
Here's How Much You Would Have Made Owning Novavax Stock In The Last 5 Years - Novavax (NASDAQ:NVAX)
Benzinga· 5 days agoNovavax NVAX has outperformed the market over the past 5 years by 5.74% on an annualized basis producing an average annual return of 18.97%. Currently, Novavax< ...